PIM Kinase Inhibitor AZD1208 for Treatment of MYC-Driven Prostate Cancer

BACKGROUND: PIM1 kinase is coexpressed with c-MYC in human prostate cancers (PCs) and dramatically enhances c-MYC-induced tumorigenicity. Here we examine the effects of a novel oral PIM inhibitor, AZD1208, on prostate tumorigenesis and recurrence. METHODS: A mouse c-MYC/Pim1-transduced tissue recomb...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Natl Cancer Inst
Main Authors: Kirschner, Austin N., Wang, Jie, van der Meer, Riet, Anderson, Philip D., Franco-Coronel, Omar E., Kushner, Max H., Everett, Joel H., Hameed, Omar, Keeton, Erika K., Ahdesmaki, Miika, Grosskurth, Shaun E., Huszar, Dennis, Abdulkadir, Sarki A.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4326311/
https://ncbi.nlm.nih.gov/pubmed/25505253
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/dju407
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados